Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

61. Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer. (PubMed)

Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer. BACKGROUND: Postoperative complications, especially pulmonary complications, affect more than half the patients who undergo open esophagectomy for esophageal cancer. Whether hybrid minimally invasive esophagectomy results in lower morbidity than open esophagectomy is unclear. METHODS: We performed a multicenter, open-label, randomized, controlled trial involving patients 18 to 75 years of age with resectable cancer of the middle (...) % (95% CI, 45 to 64) in the open-procedure group; disease-free survival was 57% (95% CI, 47 to 66) and 48% (95% CI, 38 to 57), respectively. CONCLUSIONS: We found that hybrid minimally invasive esophagectomy resulted in a lower incidence of intraoperative and postoperative major complications, specifically pulmonary complications, than open esophagectomy, without compromising overall and disease-free survival over a period of 3 years. (Funded by the French National Cancer Institute

2019 NEJM

62. Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: nested case-control study within Lung Cancer Cohort Consortium. (PubMed)

Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: nested case-control study within Lung Cancer Cohort Consortium. OBJECTIVES: To conduct a comprehensive analysis of prospectively measured circulating high sensitivity C reactive protein (hsCRP) concentration and risk of lung cancer overall, by smoking status (never, former, and current smokers), and histological sub-type. DESIGN: Nested case-control study. SETTING: 20 population based cohort studies in Asia (...) , Europe, Australia, and the United States. PARTICIPANTS: 5299 patients with incident lung cancer, with individually incidence density matched controls. EXPOSURE: Circulating hsCRP concentrations in prediagnostic serum or plasma samples. MAIN OUTCOME MEASURE: Incident lung cancer diagnosis. RESULTS: A positive association between circulating hsCRP concentration and the risk of lung cancer for current (odds ratio associated with a doubling in hsCRP concentration 1.09, 95% confidence interval 1.05

2019 BMJ

63. Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer. (PubMed)

Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer. BACKGROUND: People with cancer with febrile neutropenia are at risk of severe infections and mortality and are thus treated empirically with broad-spectrum antibiotic therapy. However, the recommended duration of antibiotic therapy differs across guidelines. OBJECTIVES: To assess the safety of protocol-guided discontinuation of antibiotics regardless of neutrophil (...) count, compared to continuation of antibiotics until neutropenia resolution in people with cancer with fever and neutropenia, in terms of mortality and morbidity. To assess the emergence of resistant bacteria in people with cancer treated with short courses of antibiotic therapy compared with people with cancer treated until resolution of neutropenia. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 10) in the Cochrane Library, MEDLINE, Embase

2019 Cochrane

64. Management Guidelines for Children With Thyroid Nodules and Differentiated Thyroid Cancer

Management Guidelines for Children With Thyroid Nodules and Differentiated Thyroid Cancer Management Guidelines for Children With Thyroid Nodules and Differentiated Thyroid Cancer | From the American Academy of Pediatrics | Pediatrics '); document.write(''); } function OAS_AD(pos) { if (OAS_version >= 11 && typeof(OAS_RICH)!='undefined') { OAS_RICH(pos); } else { OAS_NORMAL(pos); } } //--> Search for this keyword Source User menu Sections . Sign up for highlighting editor-chosen studies (...) with the greatest impact on clinical care. Watch the to learn more about Pediatrics . Management Guidelines for Children With Thyroid Nodules and Differentiated Thyroid Cancer In July 2015, the American Academy of Pediatrics endorsed the following publication: Francis GL, Waguespack SG, Bauer AJ, et al; The American Thyroid Association Guidelines Task Force on Pediatric Thyroid Cancer. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid . 2015;25(7):716–759. doi

2019 American Academy of Pediatrics

65. A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer

A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer 30482524 2018 12 18 1097-685X 157 1 2019 Jan The Journal of thoracic and cardiovascular surgery J. Thorac. Cardiovasc. Surg. A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer. 362-373.e8 S0022-5223(18)32347-X 10.1016/j.jtcvs.2018.08.075 Stereotactic body radiation (...) therapy is the preferred treatment modality for patients with inoperable early-stage non-small cell lung cancer. However, comparative outcomes between stereotactic body radiation therapy and surgery for high-risk patients remain controversial. The primary aim of the present meta-analysis was to assess overall survival in matched and unmatched patient cohorts undergoing stereotactic body radiation therapy or surgery. Secondary end points included cancer-specific survival, disease-free survival, disease recurrence

2019 EvidenceUpdates

66. Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer P Pembrolizumab with pemetre embrolizumab with pemetrex xed and ed and platinum chemother platinum chemotherap apy for untreated, y for untreated, metastatic, non-squamous non-small-cell metastatic, non-squamous non-small-cell lung cancer lung cancer T echnology appraisal guidance Published: 10 January 2019 nice.org.uk/guidance/ta557 © NICE 2019. All rights reserved (...) . They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non- squamous non

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

67. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer 1 Special Article Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer; a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS Authors Y-L. Wu 1 , D. Planchard 2 , S. Lu 3 , H. Sun 4 , N. Yamamoto 5 , D-W. Kim 6 , D. S. W. Tan 7 , J. C-H. Yang 8 , M. Azrif 9 , T. Mitsudomi 10 , K. Park 11 , R (...) . A. Soo 12 , J.W.C. Chang 13 , A. Alip 14 , S. Peters 15 , J-Y. Douillard 16 Affiliations 1 Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China; 2 Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif, France; 3 Shanghai Chest Hospital, Shanghai, P.R. China; 4 Guangdong Lung Cancer Institute, Guangdong Lung Cancer Institute, Guangdong General Hospital, School of Medicine, South China University of Technology

2019 European Society for Medical Oncology

68. Guidelines on Management of Dyspnea (Breathlessness) in Patients with Cancer

Guidelines on Management of Dyspnea (Breathlessness) in Patients with Cancer Evidence Summary SMG-3 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Guidelines on Management of Dyspnea (Breathlessness) in Patients with Cancer Glenn G. Fletcher Report Date: December 13, 2018 For information about this document, please contact the lead author through the PEBC via: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca (...) For information about the PEBC and the most current version of all reports, please visit the CCO website at https://www.cancercareontario.ca/en/guidelines-advice or contact the PEBC office at: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca PEBC Report Citation (Vancouver Style): Fletcher GG. Guidelines on management of dyspnea (breathlessness) in patients with cancer. Toronto (ON): Cancer Care Ontario; 2018 Dec 13. Program in Evidence-Based Care Evidence Summary No.: SMG-3

2019 Cancer Care Ontario

69. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer

Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer T T umour profiling tests to guide adjuvant umour profiling tests to guide adjuvant chemother chemotherap apy decisions in early breast y decisions in early breast cancer cancer Diagnostics guidance Published: 19 December 2018 nice.org.uk/guidance/dg34 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our (...) of implementing NICE recommendations wherever possible. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 56Contents Contents 1 Recommendations 4 2 Clinical need and practice 6 The problem addressed 6 The condition 7 The diagnostics and care pathways 7 3 The diagnostic tests 9 The interventions 9 The comparator 13 4 Evidence 14

2019 National Institute for Health and Clinical Excellence - Diagnostics Guidance

70. Management of Squamous Cell Cancer of the Vulva?

Management of Squamous Cell Cancer of the Vulva? Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Copyright © 2019 Inc. All rights reserved. | | | | | | The content on this site is intended for health professionals. We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the . Advertisements on this site do not constitute a guarantee or endorsement by the journal

2019 Society of Obstetricians and Gynaecologists of Canada

71. Pertuzumab (Perjeta) - in adult patients with HER2 positive metastatic or locally recurrent unresectable breast cancer

Pertuzumab (Perjeta) - in adult patients with HER2 positive metastatic or locally recurrent unresectable breast cancer 1 Published 14 January 2019 1 a SMC2120 pertuzumab 420mg concentrate for solution for infusion (Perjeta®) Roche Products Limited 7 December 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE (...) : following a third resubmission assessed under the orphan equivalent process pertuzumab (Perjeta ® ) is accepted for use within NHSScotland. Indication under review: In combination with trastuzumab and docetaxel, in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. Addition of pertuzumab to current first-line treatment, trastuzumab plus docetaxel, significantly

2019 Scottish Medicines Consortium

72. Larotrectinib (Vitrakvi) - To treat patients whose cancers have a specific genetic feature (biomarker)

Larotrectinib (Vitrakvi) - To treat patients whose cancers have a specific genetic feature (biomarker) Drug Approval Package: Vitrakvi (larotrectinib) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Vitrakvi (larotrectinib) Company: Place company name here Application Number: 210861 &211710 Approval Date: 11/26/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter

2019 FDA - Drug Approval Package

73. Trastuzumab (Ogivri) - breast cancer or stomach cancer

Trastuzumab (Ogivri) - breast cancer or stomach cancer 1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions 1. NAME OF THE MEDICINAL PRODUCT Ogivri 150 mg powder for concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One (...) for solution for infusion (powder for concentrate). White to pale yellow lyophilised powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Breast cancer Metastatic breast cancer Ogivri is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC): - as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless

2019 European Medicines Agency - EPARs

74. Adjuvant Endocrine Therapy for Women With Hormone Receptor?Positive Breast Cancer

Adjuvant Endocrine Therapy for Women With Hormone Receptor?Positive Breast Cancer ');//--> ');//--> Search in: Menu Captcha ASCO Family of Sites Journals Publications Education Other Sites 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2018 American Society of Clinical Oncology |

2019 American Society of Clinical Oncology Guidelines

75. Evaluating Susceptibility to Pancreatic Cancer

Evaluating Susceptibility to Pancreatic Cancer ');//--> ');//--> Search in: Menu Captcha ASCO Family of Sites Journals Publications Education Other Sites 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2018 American Society of Clinical Oncology |

2019 American Society of Clinical Oncology Guidelines

76. ASTRO Guideline on Palliative Radiation Therapy for Non-small Cell Lung Cancer (NSCLC) - Update

ASTRO Guideline on Palliative Radiation Therapy for Non-small Cell Lung Cancer (NSCLC) - Update Practical Radiation Oncology Email/Username: Password: Remember me Search Terms Search within Search Share this page: Copyright © 2019 Inc. All rights reserved. | | | | | | The content on this site is intended for health professionals. We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the . Advertisements on this site do not constitute

2019 American Society for Radiation Oncology

77. A Systematic Review and Meta-Analysis of the Safety, Feasibility, and Effect of Exercise in Women With Stage II+ Breast Cancer

A Systematic Review and Meta-Analysis of the Safety, Feasibility, and Effect of Exercise in Women With Stage II+ Breast Cancer 29730319 2018 11 24 1532-821X 99 12 2018 Dec Archives of physical medicine and rehabilitation Arch Phys Med Rehabil A Systematic Review and Meta-Analysis of the Safety, Feasibility, and Effect of Exercise in Women With Stage II+ Breast Cancer. 2621-2636 S0003-9993(18)30280-6 10.1016/j.apmr.2018.03.026 To systematically evaluate the safety, feasibility, and effect (...) of exercise among women with stage II+ breast cancer. CINAHL, Cochrane, Ebscohost, MEDLINE, Pubmed, ProQuest Health and Medical Complete, ProQuest Nursing and Allied Health Source, Science Direct and SPORTDiscus were searched for articles published before March 1, 2017. Randomized, controlled, exercise trials involving at least 50% of women diagnosed with stage II+ breast cancer were included. Risk of bias was assessed and adverse event severity was classified using the Common Terminology Criteria

2019 EvidenceUpdates

78. Impact of breathing exercises in subjects with lung cancer undergoing surgical resection: A systematic review and meta-analysis

Impact of breathing exercises in subjects with lung cancer undergoing surgical resection: A systematic review and meta-analysis 30357997 2018 11 21 1365-2702 2018 Oct 24 Journal of clinical nursing J Clin Nurs Impact of breathing exercises in subjects with lung cancer undergoing surgical resection: A systematic review and meta-analysis. 10.1111/jocn.14696 To assess the effects of breathing exercises on postoperative pulmonary complications (PPCs), pulmonary function, 6-min walk distance (6MWD (...) ) and the length of hospital stay (LOS) in lung cancer patients undergoing lung surgery. Lung cancer patients undergoing lung resection have poor pulmonary function and multiple PPCs. Breathing exercises may improve these symptoms. Systematic literature review and meta-analysis were conducted. All entries to the following databases were searched up until 20 December 2017: PubMed, EMBASE Ovid, the Cochrane Central Register of Randomized Controlled Trials, Web of Science, Wanfang, Weipu and Chinese National

2019 EvidenceUpdates

79. Genetic cancer risk assessment in general practice: systematic review of tools available, clinician attitudes, and patient outcomes

Genetic cancer risk assessment in general practice: systematic review of tools available, clinician attitudes, and patient outcomes 30510097 2018 12 04 1478-5242 2018 Dec 03 The British journal of general practice : the journal of the Royal College of General Practitioners Br J Gen Pract Genetic cancer risk assessment in general practice: systematic review of tools available, clinician attitudes, and patient outcomes. bjgp18X700265 10.3399/bjgp18X700265 A growing demand for cancer genetic (...) services has led to suggestions for the involvement of GPs. How, and in which conditions, they can be involved, and whether there are important barriers to implementation should be ascertained. To review the tools available, clinician attitudes and experiences, and the effects on patients of genetic cancer risk assessment in general practice. Systematic review of papers published worldwide between 1996 and 2017. The MEDLINE (via Ovid), EMBASE, Cochrane Library, CINAHL, and PsycINFO databases and grey

2019 EvidenceUpdates

80. Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review

Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review 30391078 2018 11 04 1873-7560 2018 Oct 31 European urology Eur. Urol. Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review. S0302-2838(18)30836-4 10.1016/j.eururo.2018.10.041 Identification of early nodal recurrence after primary prostate cancer (PCa) treatment by functional imaging may guide metastasis-directed therapy such as salvage lymph node dissection (SLND). The aim (...) of the effectiveness of SLND were the retrospective design of single-center series, heterogeneity between series in terms of adjuvant treatment, endpoints, definitions of progression and study population, as well as the absence of long-term follow-up. A growing body of accumulated data suggests that SLND is a safe metastasis-directed therapy option in nodal recurrence after primary treatment. However, to date, high level of evidence is still missing to draw any clinically meaningful conclusion about

2019 EvidenceUpdates